Can prognostic factors be applied in treatment selection for aggressive lymphoma patients?
Coiffier
B
B
Department of Haematology, Centre Hospitalier Lyon-SUD, Hospices Civils de Lyon, France.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012709:Serum Albumin / Q000032:analysis; D014750:Vincristine / Q000627:therapeutic use
D012709:Serum Albumin; D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide